FDA Confirms Endpoints of Androxal Study
July 16, 2014 at 09:21 AM EDT
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced it has received additional guidance from the FDA regarding primary endpoints ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.